Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks

FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.

    PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y

    PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.

      Is a Beat in Store for Ionis (IONS) This Earnings Season?

      Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.

        Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y

        Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.

          Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up

          Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.

            Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco

            Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.

              Biogen (BIIB) Beats on Q3 Earnings and Revenue

              Biogen's third quarter 2017 earnings were better-than expected. Revenues also surpassed estimates during the quarter.

                Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

                  Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?

                  At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

                    Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

                      Tracey Ryniec headshot

                      Where to Find Value in Healthcare Stocks

                      The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

                        Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit

                        Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.

                          ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status

                          ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.

                            Catabasis' DMD Candidate Slows Disease Progression, Stock Up

                            Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

                              Ligand (LGND) Signs Deal to Acquire Crystal Bioscience

                              Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.

                                Celsion's Immunotherapy Candidate Impresses, Stock Surges

                                Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.

                                  Emergent Completes Acquisition of Anthrax Drug Raxibacumab

                                  Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.

                                    Allergan's Botox Gets FDA Nod for Forehead Line Treatment

                                    Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.

                                      Amgen Enters Into an Immuno-Oncology Partnership With CytomX

                                      Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.

                                        Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen

                                        Zacks.com featured highlights include article Texas Instruments, Applied Materials, Pepsico, CBRE Group and Biogen

                                          Endocyte Inks Deal For Prostate Cancer Candidate, Shares Up

                                          Endocyte (ECYT) acquired an exclusive worldwide license to develop and commercialize ABX GmbH's phase III-ready prostate cancer candidate 177Lu-PSMA-617.

                                            Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy

                                            Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.

                                              Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA

                                              Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.

                                                Supriyo Bose headshot

                                                5 Top ROE Stocks to Buy as Markets Snub Geopolitical Threats

                                                ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

                                                  The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern

                                                  The Zacks Analyst Blog Highlights: Procter & Gamble, PetroChina, Biogen, Accenture and Norfolk Southern